Gilead Sciences sells $3 billion in senior notes due 2028 to 2034
Gilead Sciences issued $3.0 billion of senior notes in four tranches, under an underwriting agreement dated May 14, 2026, and a supplemental indenture dated May 20, 2026. The company said it will use the net proceeds for general corporate purposes, which may include acquisitions, investments and other strategic transactions.
Key points
- Four series: $500 million 4.250% notes due 2028, $1.0 billion 4.400% notes due 2029, $1.0 billion 4.600% notes due 2031, and $500 million 4.900% notes due 2034
- Notes were sold in a public offering under shelf registration Form S-3 (File No. 333-273745); underwriters include Barclays Capital, BofA Securities and Citigroup Global Markets
- Indenture restricts secured debt, sale and leaseback transactions, and mergers or asset transfers, and requires an offer to repurchase notes upon certain change of control events
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.